Health Catalyst (NASDAQ:HCAT) Price Target Lowered to $11.00 at Piper Sandler

Health Catalyst (NASDAQ:HCAT) had its target price decreased by Piper Sandler from $14.00 to $11.00 in a research note published on Monday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

A number of other equities analysts have also recently issued reports on HCAT. Stephens decreased their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an equal weight rating on the stock in a research report on Thursday, August 8th. Cantor Fitzgerald reiterated an overweight rating and issued a $16.00 price objective on shares of Health Catalyst in a report on Tuesday, August 20th. Evercore ISI reduced their target price on Health Catalyst from $9.00 to $8.00 and set an outperform rating on the stock in a research note on Tuesday, July 9th. Wells Fargo & Company dropped their price target on Health Catalyst from $14.00 to $13.00 and set an overweight rating for the company in a research note on Friday, May 10th. Finally, Canaccord Genuity Group reissued a buy rating and set a $11.00 price objective on shares of Health Catalyst in a research report on Tuesday, May 21st. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Health Catalyst has an average rating of Moderate Buy and an average price target of $11.25.

Health Catalyst Trading Down 1.5 %

NASDAQ HCAT opened at $7.16 on Monday. The stock has a 50-day moving average of $6.69 and a 200-day moving average of $7.05. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $12.05. The firm has a market cap of $422.69 million, a PE ratio of -3.87 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative return on equity of 11.86% and a negative net margin of 35.56%. The firm had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. The business’s revenue was up 3.7% on a year-over-year basis. As a group, equities research analysts forecast that Health Catalyst will post -0.4 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $6.19, for a total value of $32,243.71. Following the sale, the chief operating officer now owns 150,006 shares in the company, valued at approximately $928,537.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 13,035 shares of company stock worth $81,396. Insiders own 2.70% of the company’s stock.

Institutional Trading of Health Catalyst

Institutional investors have recently bought and sold shares of the company. First Light Asset Management LLC lifted its stake in shares of Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after buying an additional 3,221,408 shares in the last quarter. Millennium Management LLC raised its holdings in Health Catalyst by 96.3% in the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after acquiring an additional 1,184,131 shares during the last quarter. Kennedy Capital Management LLC bought a new position in Health Catalyst in the 1st quarter valued at approximately $8,780,000. Primecap Management Co. CA boosted its stake in Health Catalyst by 14.7% during the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after purchasing an additional 305,079 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Health Catalyst in the 1st quarter worth $1,848,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.